- Current report filing (8-K)
21 July 2009 - 6:16AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): July 20, 2009
Idenix
Pharmaceuticals, Inc.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
000-49839
|
45-0478605
|
|
(State
or Other
Juris
diction
of Incorporation)
|
(Commission
File
Number)
|
(IRS
Employer
Identification
No.)
|
|
60
Hampshire Street
Cambridge,
MA
|
02139
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: 617-995-9800
(Former
Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions (
see
General Instruction A.2.
below):
¨
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
Item 2.02. Results of
Operations and Financial Condition
On July 20, 2009,
Idenix Pharmaceuticals
, Inc. (the “Company”) announced its
financial results for the quarter ended June 30, 2009. The full text
of the press release issued in connection with the announcement is furnished as
Exhibit 99.1 to this Current Report on Form 8-K.
The information in Item 2.02 of this
Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of
Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or
otherwise subject to the liabilities of that section, nor shall it be deemed
incorporated by reference in any filing under the Securities Act of 1933 or the
Exchange Act, except as expressly set forth by specific reference in such a
filing.
Item
7.
01.
Regulation FD
Disclosure
On July 20, 2009, the Company also
announced that it had successfully completed a three-day proof-of-concept study
of IDX184, a novel liver-targeted pro-drug of 2’-methyl guanosine nucleotide,
for the treatment of the hepatitis C virus. The full text of the
press release issued in connection with the announcement is filed as Exhibit
99.2 to this Current Report on Form 8-K and incorporated herein by
reference.
Item 9.01. Financial
Statements and Exhibits
(d)
Exhibits
The following exhibit relating to Item
2.02 shall be deemed to be furnished, and not filed:
99.1
Press Release entitled “Idenix
Pharmaceuticals Reports Second Quarter and Six Month 2009 Financial Results,”
dated July 20, 2009.
The following exhibit relating to Item
7.01 shall be deemed to be filed:
99.2 Press
Release entitled “Idenix Pharmaceuticals Successfully Completes Proof-of-Concept
Study of IDX184 for the Treatment of Hepatitis C Virus (HCV),” dated July 20,
2009.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the Registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
Idenix
Pharmaceuticals, Inc.
|
|
|
|
|
|
|
|
Date: July
20, 2009
|
By:
|
/s/ Ronald
C. Renaud, Jr.
|
|
|
|
|
Ronald
C. Renaud, Jr.
Chief
Financial Officer
|
|
EXHIBIT
INDEX
|
Exhibit
No.
|
Description
|
|
|
|
|
99.1
|
Press Release entitled
“
Idenix
Pharmaceuticals
Reports Second Quarter and Six Month 2009 Financial Results,” dated July
20, 2009.
|
|
|
|
|
99.2
|
Press
Release entitled “Idenix Pharmaceuticals Successfully Completes
Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus
(HCV),” dated July 20, 2009.
|
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jun 2024 to Jul 2024
(MM) (NASDAQ:IDIX)
Historical Stock Chart
From Jul 2023 to Jul 2024
